Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
How do you treat metastatic breast cancer which is HR positive, Her2 negative with PIK3CA+ and high tumor mutational burden (>10) who progressed after prior ET+CDK 4/6 and PIK3CA inhibitor therapy?
Related Questions
Would you give T-DXd to patients with resolved drug-induced ILD from other agents such as prior chemo/targeted therapy/immunotherapy?
What is your approach in treatment of oligometastatic triple negative inflammatory breast cancer?
What is the current paradigm for breast cancer diagnosed with isolated metastases prior to initial treatment?
What are your top takeaways in Breast Cancer from ASCO 2023?
How reliable is the liquid biopsy on patients with progressing HER2 positive breast cancer with negative HER2 on liquid testing?
Do you routinely check echocardiograms on all patients who are starting TDM1?
Do you recommend the use of elacestrant after prior fulvestrant in metastatic hormone positive breast cancer?
Do you start systemic therapy for patients with previously localized HR+ breast cancer developing solitary bone metastasis which is now triple negative if there are no other sites of disease after metastasis-directed radiation?
Would you use elacestrant in a patient with an ESR1-AKAP12 fusion?
What is your treatment approach in a male with ER+ Her2+ metastatic breast cancer who received TCHP but developed irreversible cardiomyopathy?
